First Patient dosed in Ph 1/1b Clinical Trial of QTX3046
“We are pleased to now have two KRAS inhibitor programs in the clinic focused on treating G12D-mutated cancers,” said Leonardo Faoro, MD, MBA, Chief Medical Officer of Quanta Therapeutics. “The combination treatment with KRAS and EGFR inhibitors has shown promising efficacy in multiple KRASG12C-mutated tumor types. In order to achieve similar breakthroughs against the more prevalent G12D mutation, it will require oral small molecules with direct inhibition of the target and properties enabling use in combination treatments. We believe we are leading the field with the combination of oral, direct inhibition of KRASG12D and EGFR antibody therapy for difficult-to-treat solid tumors.”
Share:
More News
“Antengene announced it has entered into a global clinical collaboration with MSD to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate (ADC), and MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced solid tumors. At the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025), Antengene
“Advanced esophageal squamous cell carcinoma is a difficult-to-treat disease, and unfortunately overall survival remains low,” said Marjorie Green, MD, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “The initiation of the pivotal Phase 3 IDeate-Esophageal01 clinical trial demonstrates our shared commitment with Daiichi Sankyo to
“Overall response rate (ORR) was 97% (114/117) with a complete response/stringent complete response (CR/sCR) rate of 68% (79/117) and a very good partial response or higher (>VGPR) rate of 85% (100/117), per International Myeloma Working Group (IMWG) criteria as investigator-assessed. Of those evaluable for minimal residual disease (MRD) testing at
“EMA approval of the MIRACLE trial protocol is a huge milestone for us. Although we’re already seeing recruitment in our first non-EU country, we believe that this expansion into the EU really supercharges our recruitment potential,” said Walter Klemp, Chairman and CEO of Moleculin. “Importantly, when combined with the sites
